logo
Media Companies Like Paramount Should Think Twice Before Settling With Trump

Media Companies Like Paramount Should Think Twice Before Settling With Trump

Yahoo09-07-2025
This article is part of TPM Cafe, TPM's home for opinion and news analysis.
Paramount Global, which owns CBS News, recently made a perilous decision to settle the lawsuit that Donald Trump brought against them last year. Trump's suit asserted that CBS' 60 Minutes illegally edited a Kamala Harris interview in order to hurt his chances in the 2024 presidential race. Before settling, Paramount validly argued Trump's legal theories were meritless and violated the company's First Amendment rights. Yet the media conglomerate settled the suit for $16 million, which it reportedly will pay toward Trump's presidential library plus other costs, although Trump asserted that the settlement is worth double that sum. The settlement decision by Paramount's board of directors carries huge legal and reputational risks — including potential bribery charges — while degrading the independent investigative journalism Americans rely on.
Many legal experts agreed from the beginning that Paramount had a strong defense, citing constitutional protections to make editorial decisions. But the company's choice to settle reportedly appears to have hinged on an unrelated $8 billion merger with Skydance Media. If the Federal Communications Commission (FCC), led by Trump ally Brendan Carr, doesn't approve this merger by October, the deal could fall apart and board chair Shari Redstone could lose a reported $2 billion payout.
While Trump's lawyers and Carr deny the lawsuit is related to these FCC proceedings, Paramount staff appeared to see a link, as did Trump himself. And as Paramount's board struggled with the prospect of facing bribery charges if it settled the suit, internal pressures for CBS News to provide more favorable coverage of Trump sparked major internal discord, resulting in two high-profile news division resignations.
Paramount found itself in a tough situation, no doubt. But the grave risks of settling with Trump are bad for the business, its shareholders, and its employees — and it represents a dangerous sign for democracy. These stakes are clear in the potential legal risks Paramount is still facing post-settlement.
First, three U.S. senators — Elizabeth Warren (D-MA), Bernie Sanders (I-VT), and Ron Wyden (D-OR) — warned Redstone in a May 19 letter that under federal law, paying Trump to help finalize merger approval could potentially be bribery of a public official. Such a charge has a five-year statute of limitations. The senators suggested that any 'scheme to curry favor with the Trump administration' compromises journalistic independence and raises corruption concerns. Immediately after the settlement, Wyden reupped these issues and asked state prosecutors to pursue criminal charges, while Warren called for an investigation.
State-level problems have surfaced, too. In California, two powerful senators who chair relevant committees already launched an inquiry, inviting two former CBS News executives to testify. The lawmakers suggested a settlement could violate California's laws against, for example, unfair competition and misuse of corporate funds, while penalizing competitors who resist political interference, distorting the media marketplace, and chilling the investigative journalism Californians depend on.
On top of that, Paramount's shareholders have already threatened legal action. The nonprofit Freedom of the Press, which owns Paramount stock, promised to sue the company if it settled with Trump and recently hired two powerhouse lawyers in preparation. On June 5, the nonprofit told Paramount's board a settlement could cause 'catastrophic' harm to the company and destroy shareholder value. They also said a settlement could illegally breach the board's duties of care and loyalty to shareholders, constitute bribery, and violate anti-competition laws in several states — which could multiply legal fees and liability.
Other long-term hazards abound. For example, a future president could take a very different look at the matter than Trump. A future Congress could hold high-profile hearings and refer the matter for Department of Justice investigation. A future DOJ could investigate potential lawbreaking, including the bribery angle. An FCC under the stewardship of a new chair could also launch investigatory proceedings. And attorneys involved in the settlement could face state disciplinary proceedings or disbarment if there is a finding that they acted illegally or unethically.
Aside from the legal risks, the trusted brand of CBS News and its credibility with the American people will likely crater. More broadly, the settlement represents yet another example of independent media companies kowtowing to an administration that appears intent on weakening perceived enemies. As the editorial board of the conservative Wall Street Journal wrote: 'The President is using government to intimidate news outlets that publish stories he doesn't like. It's a low move in a free country with a free press.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Exact Sciences to acquire US rights for Freenome's blood-based CRC test
Exact Sciences to acquire US rights for Freenome's blood-based CRC test

Yahoo

time16 minutes ago

  • Yahoo

Exact Sciences to acquire US rights for Freenome's blood-based CRC test

Freenome has entered an exclusive licence agreement with Exact Sciences, granting the latter the rights to commercialise Freenome's blood-based colorectal cancer (CRC) screening test in the US. Exact Sciences plans to accelerate the market adoption of the CRC blood test by leveraging its commercial infrastructure. Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November. Freenome is set to receive up to an additional $700m, contingent upon reaching specific milestones related to its CRC screening tests. These milestones include a $100m payment upon receiving first-line approval from the Food and Drug Administration (FDA) for their inaugural test and another $100m for the approval of a subsequent, next-generation test that meets or exceeds certain performance criteria, such as a minimum of 19% advanced precancerous lesions (APL) sensitivity and 83% overall CRC sensitivity. However, should the performance fall below these benchmarks, the payment would be adjusted accordingly. Furthermore, Freenome could earn $500m if its test is classified as a first-line A or B test in the US Preventive Services Taskforce (USPSTF) guidelines or if it achieves certain payer-contracted coverage requirements. Again, a decreased payment is applicable if the test is included in the USPSTF guidelines as a second-line A or B test. Freenome could be entitled to obtain royalties that vary between 0% and 10%, depending on the profitability of the test, while also adhering to standard provisions for royalty stacking. However, if specific conditions are not fulfilled, Exact Sciences reserves the right to end the agreement. Exact Sciences noted that it is committed to investing $20m annually over three years in joint research and development to further utilise the technology. Freenome retains rights to its CRC blood test when combined with other cancer screening tests. The license agreement also includes a senior convertible note purchase by Exact Sciences, amounting to $50m, with a coupon rate of 5% due in 2030. Freenome's PREEMPT CRC Study, which involved nearly 49,000 adults at average risk, demonstrated the CRC test's ability to identify 81.1% of CRC, including 63.5% at stage one, and 13.7% of APL, with a specificity of 90.4%. Freenome is also working on an 'improved version' of the test, which has shown enhanced performance in detection rates, and plans to submit a supplemental premarket approval application to the FDA once final clinical validation data are available. In a recent development, Exact Sciences expanded its collaboration with private insurer Humana to make the Cologuard Plus test available to eligible Humana Medicare Advantage members as an in-network service across the US. "Exact Sciences to acquire US rights for Freenome's blood-based CRC test" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

British man charged with attempting to drown daughter-in-law during US holiday
British man charged with attempting to drown daughter-in-law during US holiday

Yahoo

time16 minutes ago

  • Yahoo

British man charged with attempting to drown daughter-in-law during US holiday

A British man has been charged by US police with the attempted murder of his daughter-in-law after allegedly trying to drown her in a swimming pool while on holiday, local authorities said. Mark Raymond Gibbon, 62, of Beaconsfield, Buckinghamshire, allegedly tried to drown the 33-year-old woman after they argued about his grandchildren in their rental home at the Solterra Resort in Davenport, Florida, on Sunday, Polk County Sheriff Grady Judd said on X. Officers had responded to reports of a disturbance in a back-yard swimming pool at around 5.20pm local time. Gibbon allegedly pushed and held the victim's head under water multiple times which prevented her from breathing, Mr Judd said. He allegedly only stopped after holidaymakers next door said they had called the sheriff's office, while the victim's nine-year-old daughter jumped into the pool to try to stop the incident, the sheriff said. Gibbon was arrested and taken to Polk County Jail before he was charged with attempted second-degree murder and battery, Mr Judd said. The sheriff said in a statement: 'It's great that Polk County draws visitors from all across the world, but we expect vacationers to behave while they visit with us, just as we expect our lifelong residents to do the same. 'Because Mr Gibbon couldn't control his anger, he may find himself spending a lot more time in Florida than he had anticipated.'

NiCE Provides Webcast and Dial-in Details for its Second Quarter 2025 Results Teleconference
NiCE Provides Webcast and Dial-in Details for its Second Quarter 2025 Results Teleconference

Yahoo

time16 minutes ago

  • Yahoo

NiCE Provides Webcast and Dial-in Details for its Second Quarter 2025 Results Teleconference

HOBOKEN, N.J., August 07, 2025--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) will announce its second quarter 2025 results on Thursday, August 14, 2025, before the opening of the NASDAQ Stock Exchange. Later that day, management will host a conference call to discuss the results. 8:30 AM - Eastern1:30 PM - UK3:30 PM - Israel The call will be webcast live on the Company's website at Please register with the relevant link for either the webcast or dial-in on our "upcoming event page." Kind Regards,NiCE Investor Relations About NiCENiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes. Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: View source version on Contacts Investor Relations Contact Marty Cohen, +1-551-256-5354, ir@ ETOmri Arens, +972-3-763-0127, ir@ CET Corporate Media Contact Christopher Irwin-Dudek, 201-561-4442, media@ ET Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store